Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC
No Thumbnail Available
Identifiers
Date
2018-10-01
Authors
Garassino, M.
Cho, B. C.
Kim, J.
Mazieres, J.
Vansteenkiste, J.
Lena, H. H.
Corral, J.
Gray, J.
Powderly, J.
Chouaid, C.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
durvalumab, programmed cell death ligand-1, Immunotherapy